• Serkan Bayram, Turgut Akgül, Ali Ekrem Adıyaman, Şahin Karalar, Duygu Dölen, and Aydın Aydoseli.
• Department of Orthopedics and Traumatology, Istanbul University Faculty of Medicine, Istanbul, Turkey. Electronic address: dr.serkanbayram89@gmail.com.
• World Neurosurg. 2020 Jun 1; 138: e354-e360.

ObjectiveThe aim to evaluate central sarcopenia, as measured by psoas cross-sectional area on admission imaging, is associated with outcomes in patients with vertebral compression fractures (VCFs) treated with percutaneous vertebral augmentation treatment.MethodsWe evaluated the records of patients aged >60 years treated with vertebroplasty or kyphoplasty between 2009 and 2018 for osteoporotic VCFs. The Social Security Death Index was used to determine death. We used the psoas:lumbar vertebral index (PLVI), calculated using the cross-sectional area of the L4 vertebral body and the left and right psoas muscles, to assess for sarcopenia. A multivariate Cox algorithm was applied to recognize factors independently associated with survival.ResultsA total of 103 patients were included with an average age of 72.3 years. During the study period, 22 (21.4%) patients were deceased, whereas 81 (78.6%) were alive. The survival rates at 1 month, 6 months, and 1 year after surgery were 99%, 94.1%, and 88.4%, respectively. PLVI measurements ranged from 0.24-1.19 with a mean of 0.59 ± 0.17 and a median of 0.603. A total of 51 patients with a median value of 0.603 were defined as low PLVI group, and 52 patients with a median value of ≥0.603 were defined as the high PLVI group. PLVI was significantly low in patients who died. Age, American Society of Anesthesiologists score, and PLVI value were independently associated with a poor overall survival.ConclusionsThere is a significant correlation between sarcopenia and postoperative mortality after vertebral augmentation procedure in patients with VCFs.Copyright © 2020 Elsevier Inc. All rights reserved.

32 keywords...

hide…